Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring
Alfonso GalderisiDulanjalee KariyawasamAthanasia StoupaAdrien Nguyen QuocGraziella PintoMagali ViaudSéverine BrabantJacques BeltrandMichel PolakDinane Samara‐Boustani
0
Citation
0
Reference
10
Related Paper
Abstract:
Journal Article Accepted manuscript Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring Get access A Galderisi, A Galderisi Yale University, Pediatrics; Hopital Necker-Enfants, Malades, Pediatrics Corresponding author: Email: alfonso.galderisi@yale.edu, alfonsogalderisi@gmail.com https://orcid.org/0000-0001-8885-3056 Search for other works by this author on: Oxford Academic Google Scholar D Kariyawasam, D Kariyawasam HP Centre, Department of Paediatric Endocrinology; Université Paris Cité, Pediatrie; Université Sorbonne Paris Cité, Pediatrie Search for other works by this author on: Oxford Academic Google Scholar A Stoupa, A Stoupa Hopital universitaire Necker-Enfants malades, Paediatric Endocrinology, Diabetology and Gynaecology Department Nguyen Search for other works by this author on: Oxford Academic Google Scholar A Quoc, A Quoc Hôpital Universitaire Necker-Enfants Malades, Pediatric endocrinology https://orcid.org/0000-0002-1601-156X Search for other works by this author on: Oxford Academic Google Scholar G Pinto, G Pinto Hôpital universitaire Necker-Enfants malades, Pediatric Endocrinology, Gynecology and Diabetology Unit https://orcid.org/0000-0002-5237-0631 Search for other works by this author on: Oxford Academic Google Scholar M Viaud, M Viaud Hopital universitaire Necker-Enfants malades, Endocrinology, diabetology and gynecology unit Search for other works by this author on: Oxford Academic Google Scholar S Brabant, S Brabant APHP, Laboratoire d'Explorations Fonctionnelles, Hôpital Necker-Enfants Malades, AP-HP Centre Université de Paris, Paris, France Search for other works by this author on: Oxford Academic Google Scholar J Beltrand, J Beltrand Hopital universitaire Necker-Enfants malades, Paediatric Endocrinology, Diabetology and Gynaecology Department; Université Sorbonne Paris Cité, Faculté de Médecine; Institut Cochin, INSERM U1016; Institut Imagine Institut des Maladies Genetiques, Affiliate INSERM U1163 https://orcid.org/0000-0002-3759-3490 Search for other works by this author on: Oxford Academic Google Scholar M Polak, M Polak Hôpital universitaire Necker-Enfants malades, Pediatric endocrinology gynecology and diabetology Search for other works by this author on: Oxford Academic Google Scholar D Samara-Boustani D Samara-Boustani Samara-Boustani, Dinane; Hopital universitaire Necker-Enfants malades, Service d'Endocrinologie et Diabétologie pédiatrique https://orcid.org/0000-0002-1135-933X Search for other works by this author on: Oxford Academic Google Scholar European Journal of Endocrinology, lvae042, https://doi.org/10.1093/ejendo/lvae042 Published: 26 April 2024 Article history Received: 13 March 2024 Accepted: 20 March 2024 Published: 26 April 2024Keywords:
Diabetology
Pediatric endocrinology
Abstract This Position Statement updates the different components of the therapy of obesity (lifestyle intervention, drugs, and surgery) in children and adolescents, previously reported in the consensus position statement on pediatric obesity of the Italian Society of Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics. Lifestyle intervention is the first step of treatment. In children older than 12 years, pharmacotherapy is the second step, and bariatric surgery is the third one, in selected cases. Novelties are available in the field of the medical treatment of obesity. In particular, new drugs demonstrated their efficacy and safety and have been approved in adolescents. Moreover, several randomized control trials with other drugs are in process and it is likely that some of them will become available in the future. The increase of the portfolio of treatment options for obesity in children and adolescents is promising for a more effective treatment of this disorder.
Diabetology
Pediatric endocrinology
Position statement
Pediatric Infectious Disease
Cite
Citations (23)
Pediatric endocrinology
Diabetology
Cushing's disease
Cite
Citations (39)
Diabetology
Pediatric endocrinology
Cite
Citations (1)
Diabetology
Pediatric endocrinology
Cite
Citations (0)
Currently, hybrid closed loop (HCL) systems represent the most advantageous therapeutic option for people with diabetes requiring intensive insulin therapy. They make it possible to achieve optimal metabolic control of the disease in any age group while improving the quality of life of children and adolescents with diabetes and their families. Therefore, we present recommendations for the use of HCL systems in children and adolescents focusing on systems currently available in Poland. These systems should be the first choice in terms of method of insulin therapy in the paediatric population. They can be implemented at any stage of diabetes management. These recommendations are based on scientific evidence and experts' experience. They include principles for the initiation, optimisation, and ongoing management of HCL therapy, as well as the required HCL-related education.
Diabetology
Pediatric endocrinology
Section (typography)
Insulin delivery
Cite
Citations (0)
Diabetology
Pediatric endocrinology
Cite
Citations (0)
Diabetology
Pediatric endocrinology
Cite
Citations (3)
Diabetology
Pediatric endocrinology
Cite
Citations (0)
Diabetology
Pediatric endocrinology
Cite
Citations (0)
Diabetology
Pediatric endocrinology
Cite
Citations (0)